Source: Gladstone Institutes
Date: May 7, 2008
Summary:
In a new study, published in today’s Journal of Neuroscience, researchers in the laboratory of Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease (GIND), have determined in mouse models that modulating the activity of enkephalin peptides in the brain might reduce the cognitive deficits seen in Alzheimer’s disease.
